# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Charlotte Brontë (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI025-SYN
- Date: 2026-02-24
- Fictional facility: St. Posthumous Health Center
- Fictional author: Eleanor Thwaite, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Prenatal visit at 13 weeks with the nuchal translucency scan. **S**

## History of present illness

Ms. Brontë returns at 13 weeks 1 day. She vomits two or three times a week and eats three meals and two snacks a day. She has taken ondansetron about twice a day this week and doxylamine-pyridoxine four tablets a day. Constipation has settled with diet. Her PUQE-24 score is 7. She has begun writing again in the mornings. The cell-free DNA result came back last week as low risk for trisomies 21, 18, and 13. She had the nuchal translucency scan this morning. She has had no headache, pain, or bleeding. **S**

| Element | Detail |
|---|---|
| Interval change | Vomiting two or three times a week; three meals and two snacks a day |
| PUQE-24 | 7 (moderate), down from 9 |
| Screening | Cell-free DNA low risk; nuchal translucency scan today |
| Function | Writing again in the mornings |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Gastrointestinal | Positive | Morning nausea; vomiting two or three times a week; bowels regular |
| Neurological | Negative | No headache |
| Genitourinary | Negative | No bleeding or urinary symptoms |
| Psychiatric | Negative | Mood better; enjoying writing again |

4 systems reviewed. **S**

## Current medications

- Folic acid 0.4 mg oral tablet, one tablet by mouth daily (replacing an iron-containing prenatal vitamin while nausea is severe) **S**
- Doxylamine 10 mg and pyridoxine 10 mg delayed-release tablet, one tablet in the morning, one mid-afternoon, and two at bedtime (four a day) **S**
- Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hours as needed for nausea **S**
- Aspirin 81 mg delayed-release tablet, one tablet by mouth at bedtime **S**

## Allergies

- No known allergy **S**

## Objective

BP 106/66 mmHg; pulse 82 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 44.4 kg; BMI 19.2 kg/m². All vital signs are synthetic.

Crown-rump length: 70 mm; Nuchal translucency: 1.5 mm. All results are synthetic.

## Change since baseline

- Crown-rump length: 11 mm at baseline, 70 mm at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 44.4 kg |
| Abdomen | Soft; uterus palpable above the pubic bone |
| Fetal | Scan this morning: single live fetus, crown-rump length 70 mm, nuchal translucency 1.5 mm, nasal bone present, no structural abnormality seen |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Hyperemesis gravidarum, improving** (O21.1). PUQE-24 score 7; weight 44.4 kg, up 0.8 kg. Eating regular meals, so electrolytes need not be repeated and thiamine can stop. **S**
   - Ondansetron 4 mg up to every 8 hours only as needed.
   - Continue doxylamine-pyridoxine four tablets a day; taper once she has gone a week without vomiting.
   - Stop thiamine.
2. **First pregnancy at 38** (O09.519). Cell-free DNA screening low risk and nuchal translucency 1.5 mm: reassuring; no indication for diagnostic testing. Blood pressure 106/66 mmHg. Two moderate preeclampsia risk factors (first pregnancy and age 35 or older). **S**
   - Start aspirin 81 mg at bedtime until delivery.
   - Detailed anatomy scan at 20 weeks.
   - Glucose challenge test at 24 to 28 weeks; Tdap at 27 to 36 weeks; COVID-19 vaccine offered and she will consider it.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | PUQE-24 score (recorded in the note; no LOINC code found) | Every visit while nausea and vomiting last | Completed today | 7 (moderate), down from 9 |
| Examination | Weight against pre-pregnancy weight (46.0 kg), pulse, blood pressure, and hydration | Every visit while nausea and vomiting last | Completed today | 44.4 kg, up 0.8 kg; pulse 82 |
| Laboratory | Electrolytes, urea nitrogen, creatinine, and glucose | Until stable on oral intake | Not indicated | Not repeated: normal two weeks ago and now eating regular meals |
| Imaging | Nuchal translucency scan | Once at 11 to 14 weeks, as she chose | Completed today | Crown-rump length 70 mm; nuchal translucency 1.5 mm |
| Laboratory | Cell-free DNA screening | From 10 weeks | Completed today | Low risk for trisomies 21, 18, and 13, received last week |
| Laboratory | TSH and free T4 | In hyperemesis gravidarum; repeat at 16 to 18 weeks if suppressed | Due | Repeat planned at 16 to 18 weeks |
| Medication safety | Antiemetic effects | Every visit and after each change | Completed today | Constipation settled; ondansetron changed to as needed; thiamine stopped |
| Medication safety | Low-dose aspirin | Start at 12 to 16 weeks with risk factors; review at every visit | Completed today | Started today at 81 mg at bedtime; bleeding precautions given |
| Examination | Blood pressure | Every prenatal visit | Completed today | 106/66 mmHg; baseline for aspirin and preeclampsia surveillance |
| Examination | Fetal heart | Every prenatal visit | Completed today | Live fetus on today's scan |

## Goal progress

- Nausea and vomiting mild (PUQE-24 score 6 or less) and weight back to her pre-pregnancy 46.0 kg by about 17 weeks. In progress; target 2026-03-24. **S**
- Hydration and electrolytes normal within two weeks of any admission. Outcome by 2026-02-10: Sodium, potassium, chloride, bicarbonate, magnesium, phosphate, and transaminases all normal nine days after discharge. **S**
- An informed choice about aneuploidy screening and diagnostic testing by 13 weeks. Outcome by 2026-02-24: Chose cell-free DNA screening (low risk) and the nuchal translucency scan (1.5 mm); declined diagnostic testing. **S**
- Low-dose aspirin started between 12 and 16 weeks if indicated. Outcome by 2026-02-24: Started at 13 weeks 1 day for two moderate risk factors. **S**
- Tuberculosis screening completed and explained by the second visit. Outcome by 2026-01-20: Interferon-gamma release assay negative; no latent infection; no chest radiograph needed. **S**
- Mood screened in each trimester, with support offered. In progress; target 2026-03-24. **S**

## Medication changes

- Stopped: Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hours **S**
- Started: Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hours as needed for nausea **S**
- Stopped: Thiamine 100 mg oral tablet, one tablet by mouth three times a day **S**
- Started: Aspirin 81 mg delayed-release tablet, one tablet by mouth at bedtime **S**

## Guideline basis

- ACOG Practice Bulletin No. 189: Nausea and Vomiting of Pregnancy (2018), American College of Obstetricians and Gynecologists (Obstetrics & Gynecology)
- The Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum (Green-top Guideline No. 69) (2024), Royal College of Obstetricians and Gynaecologists (BJOG)
- Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin, Number 226 (2020), American College of Obstetricians and Gynecologists (Obstetrics & Gynecology)
- Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Preventive Medication (2021), U.S. Preventive Services Task Force

## Follow-up

- Prenatal visit at 17 weeks, with TSH and free T4. **S**
- Next scheduled visit 2026-03-24: prenatal visit at 17 weeks: nausea and vomiting review and thyroid recheck. **S**
